Pharmacokinetics of voriconazole in adult mallard ducks (Anas platyrhynchos)

References

• Mazet JAK, Newman SH, Gilardi KVK, . Advances in oiled bird emergency medicine and management. J Avian Med Surg 2002; 16: 146–149.
   Google Scholar
• Orosz SE, Frazier DL. Antifungal agents: A review of their pharmacology and therapeutic indications. J Avian Med Surg 1995; 9: 8–18.
   Google Scholar
• Orosz SE. Antifungal drug therapy in avian species. Vet Clin North Am Exot Anim Pract 2003; 6: 337–350, vi.
   PubMedGoogle Scholar
• Rochette F, Engelen M, Vanden Bossche H. Antifungal agents of use in animal health; practical applications. J Vet Pharmacol Ther 2003; 26: 31–53.
   PubMed Web of Science ®Google Scholar
• Tell LA, Craigmill AL, Clemons KV, . Studies on itraconazole delivery and pharmacokinetics in mallard ducks (Anas platyrhynchos). J Vet Pharmacol Ther 2005; 28: 267–274.
   PubMedGoogle Scholar
• Quinney SK, Galinsky RE, Jiyamapa-Serna VA, . Hydroxyitraconazole, formed during intestinal first-pass metabolism of itraconazole, controls the time course of hepatic CYP3A inhibition and the bioavailability of itraconazole in rats. Drug Metab Disposition 2008; 36: 1097–1101.
   PubMed Web of Science ®Google Scholar
• Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630–637.
   PubMed Web of Science ®Google Scholar
• Levêque D, Nivoix Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006; 27: 274–284.
   PubMed Web of Science ®Google Scholar
• Capitano B, Potoski BA, Husain S, . Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006; 50: 1878–1880.
   PubMed Web of Science ®Google Scholar
• Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623–3626.
   PubMed Web of Science ®Google Scholar
• Meneau I, Sanglard D. Azole and fungicide resistance in clinical and environmental Aspergillus fumigatus isolates. Med Mycol 2005; 43(Suppl. 1): S307–311.
   Google Scholar
• Oakley KL, Moore CB, Denning DW. In-vitro activity of voriconazole against Aspergillus spp. and comparison with itraconazole and amphotericin B. J Antimicrob Chemother 1998; 42: 91–94.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867–4875.
   PubMed Web of Science ®Google Scholar
• George D, Miniter P, Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother 1996; 40: 86–91.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 2865–2868.
   PubMed Web of Science ®Google Scholar
• Martin MV, Yates J, Hitchcock CA. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob Agents Chemother 1997; 41: 13–16.
   PubMed Web of Science ®Google Scholar
• Murphy M, Bernard EM, Ishimaru T, Armstrong D. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 696–698.
   PubMed Web of Science ®Google Scholar
• Denning DW, Ribaud P, Milpied N, . Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563–571.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Nivoix Y, Fohrer C, Natarajan-Ame S, Letscher-Bru V. Management of systemic fungal infections: alternatives to itraconazole. J Antimicrob Chemother 2005; 56 (Suppl. 1): i39–i48.
   Google Scholar
• Perfect JR, Marr KA, Walsh TJ, . Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122–1131.
   PubMed Web of Science ®Google Scholar
• Potter M. Strategies for managing systemic fungal infection and the place of itraconazole. J Antimicrob Chemother 2005; 56 (Suppl. 1): i49–i54.
   Google Scholar
• Roffey SJ, Cole S, Comby P, . The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human. Drug Metab Dispos 2003; 31: 731–741.
   PubMed Web of Science ®Google Scholar
• Andes D, Marchillo K, Stamstad T, Conklin R. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165–3169.
   PubMed Web of Science ®Google Scholar
• Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Am J Vet Res 2006; 67: 296–301.
   PubMed Web of Science ®Google Scholar
• Davis JL, Salmon JH, Papich MG. Pharmacokinetics of voriconazole after oral and intravenous administration to horses. Am J Vet Res 2006; 67: 1070–1075.
   PubMedGoogle Scholar
• Flammer K, Nettifee Osborne JA, Webb DJ, . Pharmacokinetics of voriconazole after oral administration of single and multiple doses in African grey parrots (Psittacus erithacus timneh). Am J Vet Res 2008; 69: 114–121.
   PubMedGoogle Scholar
• Sanchez-Migallon Guzman D, Flammer K, Papich MG, . Pharmacokinetics of voriconazole after oral administration of single and multiple doses in Hispaniolan Amazon parrots (Amazona ventralis). Am J Vet Res 2010; 71: 460–467.
   PubMedGoogle Scholar
• Beernaert LA, Baert K, Marin P, . Designing voriconazole treatment for racing pigeons: balancing between hepatic enzyme auto induction and toxicity. Med Mycol 2009; 47: 276–285.
   PubMed Web of Science ®Google Scholar
• Perea S, Pennick GJ, Modak A, . Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother 2000; 44: 1209–1213.
   PubMed Web of Science ®Google Scholar
• Pascual A, Nieth V, Calandra T, . Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob Agents Chemother 2007; 51: 137–143.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol 2003; 56 (Suppl. 1): 17–23.
   PubMed Web of Science ®Google Scholar
• Rex JH, Hanson LH, Amantea MA, Stevens DA, Bennett JE. Standardization of a fluconazole bioassay and correlation of results with those obtained by high-pressure liquid chromatography. Antimicrob Agents Chemother 1991; 35: 846–850.
   PubMed Web of Science ®Google Scholar
• Hoeprich PD, Finn PD. Obfuscation of the activity of antifungal antimicrobics by culture media. J Infect Dis 1972; 126: 353–361.
   PubMed Web of Science ®Google Scholar
• Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 1978; 6: 165–175.
   PubMedGoogle Scholar
• Bland JM, Altman DG. Statistical methods for assessing agreement between 2 methods of clinical measurement Lancet 1986; 1: 307–310.
   PubMed Web of Science ®Google Scholar
• R Core Development Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing. Vienna, Austria, 2009.
   Google Scholar
• Pinheiro J, Bates D, DebRoy S, Sarkar D, R Core Team. NLME: linear and nonlinear mixed effects models. 2009. R Package version 3.1–93.
   Google Scholar
• Eiden C, Peyriere H, Cociglio M, . Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother 2007; 41: 755–763.
   PubMed Web of Science ®Google Scholar
• Chen SC, Sorrell TC. Antifungal agents. Med J Aust 2007; 187: 404–409.
   PubMed Web of Science ®Google Scholar
• Quimby JM, Hoffman SB, Duke J, Lappin MR. Adverse neurologic events associated with voriconazole use in 3 cats. J Vet Intern Med 2010; 24: 647–649.
   PubMedGoogle Scholar
• Di Somma A, Bailey T, Silvanose C, Garcia-Martinez C. The use of voriconazole for the treatment of aspergillosis in falcons (Falco species). J Avian Med Surg 2007; 21: 307–316.
   PubMed Web of Science ®Google Scholar
• Cullen JM. Liver, biliary system, and exocrine pancreas. McGavin MD, Zachary JF. Pathologic Basis of Veterinary Disease. 4th. St. Louis, MO: Mosby, Inc.; 2007: 393–461.
   Google Scholar
• Crespo R, Shivaprasad HL. Developmental, metabolic, and other noninfectious disorders. Saif YM. Diseases of Poultry. 12th Ames, IA: Blackwell Publishing; 2008: 1149–1195.
   Google Scholar
• Tell LA, Clemons KV, Kline Y, . Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus. Med Mycol 2009; 47: 1–11.
   PubMedGoogle Scholar
• Burhenne J, Haefeli WE, Hess M, Scope A. Pharmacokinetics, tissue concentrations, and safety of the antifungal agent voriconazole in chickens. J Avian Med Surg 2008; 22: 199–207.
   PubMed Web of Science ®Google Scholar
• Purkins L, Wood N, Ghahramani P, . Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546–2553.
   PubMed Web of Science ®Google Scholar
• Chan HM, Duran SH, Walz PH, Ravis WR. Pharmacokinetics of voriconazole after single dose intravenous and oral administration to alpacas. J Vet Pharmacol Ther 2009; 32: 235–240.
   PubMedGoogle Scholar
• Toutain PL, Bousquet-Melou A. Bioavailability and its assessment. J Vet Pharmacol Ther 2004; 27: 455–466.
   PubMed Web of Science ®Google Scholar
• Schmidt V, Demiraj F, Di Somma A, . Plasma concentrations of voriconazole in falcons. Vet Rec 2007; 161: 265–268.
   PubMed Web of Science ®Google Scholar
• Sugar AM, Liu XP. Effect of grapefruit juice on serum voriconazole concentrations in the mouse. Med Mycol 2000; 38: 209–212.
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Gonzalez GM, Hernandez S, Bocanegra R. Improving the mouse model for studying the efficacy of voriconazole. J Antimicrob Chemother 2003; 51: 1373–1376.
   PubMed Web of Science ®Google Scholar
• Jeu L, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003; 25: 1321–1381.
   PubMed Web of Science ®Google Scholar
• Walker CH. Avian forms of cytochrome P450. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol 1998; 121: 65–72.
   PubMedGoogle Scholar
• Giorgi M, Marini S, Longo V, . Cytochrome P450-dependent monooxygenase activities and their inducibility by classic P450 inducers in the liver, kidney, and nasal mucosa of male adult ring-necked pheasants. Toxicol Appl Pharmacol 2000; 167: 237–245.
   PubMedGoogle Scholar
• Ourlin JC, Baader M, Fraser D, Halpert JR, Meyer UA. Cloning and functional expression of a first inducible avian cytochrome P450 of the CYP3A subfamily (CYP3A37). Arch Biochem Biophys 2000; 373: 375–384.
   PubMed Web of Science ®Google Scholar
• Silvanose CD, Bailey TA, Di Somma A. Susceptibility of fungi isolated from the respiratory tract of falcons to amphotericin B, itraconazole and voriconazole. Vet Rec 2006; 159: 282–284.
   PubMed Web of Science ®Google Scholar
• Beernaert LA, Pasmans F, Van Waeyenberghe L, . Avian Aspergillus fumigatus strains resistant to both itraconazole and voriconazole. Antimicrob Agents Chemother 2009; 53: 2199–2201.
   PubMed Web of Science ®Google Scholar
• Theuretzbacher U, Ihle F, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649–663.
   PubMed Web of Science ®Google Scholar
• Toutain PL, Bousquet-Melou A, Martinez M. AUC/MIC: a PK/PD index for antibiotics with a time dimension or simply a dimensionless scoring factor? J Antimicrob Chemother 2007; 60: 1185–1188.
   PubMed Web of Science ®Google Scholar
• Mouton JW, Theuretzbacher U, Craig WA, . Tissue concentrations: do we ever learn? J Antimicrob Chemother 2008; 61: 235–237.
   PubMed Web of Science ®Google Scholar